Rifaximin in the treatment of gastrointestinal diseases

1. Hartmann G, Honikel KO, Knüsel F et al. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta 1967; 145(3): 843–844.

2. Descombe JJ, Dubourg D, Picard M et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14(2): 51–56.

3. Jiang ZD, Ke S, Palazzini E et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000; 44(8): 2205–2206.

4. Pentikis HS, Connolly M, Trapnell CB et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007; 27(10): 1361–1369.

5. Trapnell CB, Connolly M, Pentikis H et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007; 41(2): 222–228.

6. Gomi H, Jiang ZD, Adachi JA et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45(1): 212–216.

7. Ruiz J, Mensa L, O’Callaghan C et al. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler’s diarrhea. Diagn Microbiol Infect Dis 2007; 59(4): 473–475.

8. Sierra JM, Navia MM, Vargas M et al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother 2001; 47(6): 904–905.

9. Amenta M, Dalle Nogare ER, Colomba C et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother 1999; 11(5): 391–395.

10. Gathe JC Jr, Mayberry C, Clemmons J et al. Resolution of severe cryptosporidial diarrhea with rifaximin in pa­tients with AIDS. J Acquir Immune Defic Syndr 2008; 48(3): 363–364. doi: 10.1097//QAI.0b013e31817beb78.

11. DuPont HL, Jiang ZD, Okhuysen PC et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005; 142(10): 805–812.

12. DuPont HL, Jiang ZD, Ericsson CD et al. Rifaximin versus ciprofloxacin for the ­treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33(11): 1807–1815.

13. Steffen R, Sack DA, Riopel L et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98(5): 1073–1078.

14. Taylor DN, Bourgeois AL, Ericsson CD et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the ­treatment of travelers’ diarrhea. Am J Trop Med Hyg 2006; 74(6): 1060–1066.

15. DuPont HL, Ericsson CD, Mathewson JJ et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. ­Digestion 1998; 59(6): 708–714.

16. Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145(8): 557–563.

17. Prantera C, Lochs H, Campieri M et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23(8): 1117–1125.

18. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007; 52(3): 737–741.

19. Mas A, Rodés J, Sunyer L et al. Comparison of rifaximin and lactitol in the ­treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38(1): 51–58.

20. DuPont HL, Ericsson CD, Farthing MJ et al. Expert review of the evidence base for self-therapy of travelers’ diarrhea. J Travel Med 2009; 16(3): 161–171. doi: 10.1111/j.1708-8305.2009.00300.x.

21. Okhuysen PC, Jiang ZD, Carlin L et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99(9): 1774–1778.

22. DuPont HL, Ericsson CD, Farthing MJ et al. Expert review of the evidence base for prevention of travelers’ diarrhea. J Travel Med 2009; 16(3): 149–160. doi: 10.1111/j.1708-8305.2008.00299.x.

23. Martinez-Sandoval F, Ericsson CD, Jiang ZD et al. Prevention of travelers’ diarrhea with rifaximin in US travelers to Mexico. J Travel Med 2010; 17(2): 111–117. doi: 10.1111/j.1708-8305.2009.00385.x.

24. Taylor DN, McKenzie R, Durbin A et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 2008; 52(3): 1179–1181.

25. DuPont HL. Systematic review: prevention of travellers’ diarrhoea. Aliment Pharmacol Ther 2008; 27(9): 741–751. doi: 10.1111/j.1365-2036.2008.03647.x.

26. Taylor DN, McKenzie R, Durbin A et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006; 42(9): 1283–1288.

27. Neff GL, Frederick T, Merchant K et al. Rifaximin reduces the risk of hospitalizations in patients with previous episodes of hepatic encephalopathy: results from a phase 3 placebo-controlled trial. Digest Dis Week 2009.

28. Pedretti G, Calzetti C, Missale G et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991; 23(4): 175–178.

29. Paik YH, Lee KS, Han KH et al. Comparison of rifaximin and lactulose for the ­treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46(3): 399–407.

30. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treat­ment with rifaximin and lactulose in pa­tients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13(2): 109–118.

31. Sharma BC, Sharma P, Lunia MK et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108(9): 1458–1463. doi: 10.1038//ajg.2013.219.

32. Bajaj JS, Heuman DM, Sanyal AJ et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8(4): e60042. doi: 10.1371/journal.pone.0060042.

33. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18(2): 353–372.

34. Kalambokis GN, Mouzaki A, Rodi M et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012; 10(7): ­815–818. doi: 10.1016/j.cgh.2012.02.025.

35. Vlachogiannakos J, Viazis N, Vasianopoulou P et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28(3): 450–455. doi: 10.1111/jgh.12070.

36. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49(6): 2087–2107. doi: 10.1002/hep.22853.

37. Ortiz J, Vila MC, Soriano G et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic pa­tients. Hepatology 1999; 29(4): 1064–1069.

38. Fernández J, Navasa M, Gómez J et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35(1): 140–148.

39. Hanouneh MA, Hanouneh IA, Hashash JG et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46(8): 709–715. doi: 10.1097//MCG.0b013e3182506dbb.

40. Lutz P, Parcina M, Bekeredjian-Ding I et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One 2014; 9(4): e93909. doi: 10.1371/journal.pone.0093909.

41. Jiang ZD, Dupont HL, La Rocco M et al. WITHRDAWN: In vitro activity of rifaximin and rifampin against clinical isolates of clostridium difficile in Houston, Texas. Anaerobe 2009.

42. Garey KW, Salazar M, Shah D et al. Rifa­mycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008; 42(6): 827–835. doi: 10.1345/aph.1K675.

43. Hecht DW, Galang MA, Sambol SP et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51(8): 2716–2719.

44. Boero M, Berti E, Morgando A et al. ­Treatment for colitis caused by Clostridium dif­ficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica 1990; 5: 74–77.

45. Johnson S, Schriever C, Galang M et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44(6): 846–848.

46. Garey KW, Jiang ZD, Bellard A et al. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009; 43(1): 91–93. doi: 10.1097//MCG.0b013e31814a4e97.

47. Garey KW, Ghantoji SS, Shah DN et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66(12): 2850–2855. doi: 10.1093/jac/dkr377.

48. Berman AL. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2007; 41(10): 932–933.

49. O’Connor JR, Galang MA, Sambol SP et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008; 52(8): 2813–2817. doi: 10.1128/AAC.00342-08.

50. Curry SR, Marsh JW, Shutt KA et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48(4): 425–429. doi: 10.1086/596315.

51. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004; 7(1): 19–28.

52. Esposito I, de Leone A, Di Gregorio G et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007; 13(45): 6016–6021.

53. Lauritano EC, Bilotta AL, Gabrielli M et al. Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab 2007; 92(11): 4180–4184.

54. Di Stefano M, Malservisi S, Veneto G et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14(5): 551–556.

55. Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103(8): 2031–2035.

56. Yang J, Lee HR, Low K et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53(1): 169–174.

57. Scarpellini E, Gabrielli M, Lauritano CE et al. High dosage rifaximin for the treat­ment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25(7): 781–786.

58. Lupascu A, Gabrielli M, Lauritano EC et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22(11–12): 1157–1160.

59. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth test­ing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52: 139–142.

60. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98(2): 412–419.

61. Posserud I, Stotzer PO, Björnsson ES et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56(6): 802–808.

62. Attar A, Flourié B, Rambaud JC et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117(4): 794–797.

63. Sharara AI, Aoun E, Abdul-Baki H et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101(2): 326–333.

64. Menees SB, Maneerattannaporn M, Kim HM et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107(1): 28–35. doi: 10.1038/ajg.2011.355.

65. Sartor RB. Microbial influences in inflam­matory bowel diseases. Gastroenterology 2008; 134(2): 577–594. doi: 10.1053//j.gastro.2007.11.059.

66. Prantera C, Zannoni F, Scribano ML et al. An antibiotic regimen for the treat­ment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91(2): 328–332.

67. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn’s disease. Curr Med Res Opin 2005; 21(8): 1165–1169.

68. Shafran I, Burgunder P. Rifaximin for the treatment of newly diagnosed ­Crohn’s disease: a case series. Am J Gastroenterol 2008; 103(8): 2158–2160. doi: 10.1111/j.1572-0241.2008.01982_16.x.

69. Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006; 12(4): 335.

70. Gionchetti P, Rizzello F, Ferrieri A et al. ­Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-control­led trial. Dig Dis Sci 1999; 44(6): 1220–1221.

71. Hurst RD, Molinari M, Chung TP et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131(5): 497–500.

72. Shen B, Achkar JP, Lashner BA et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7(4): 301–305.

73. Becker JM, Stucchi AF, Bryant DE. How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm Bowel Dis 1998; 4(2): 167–169.

74. Isaacs KL, Sandler RS, Abreu M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13(10): 1250–1255.

75. Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in pa­tients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13(6): 713–718.

76. Abdelrazeq AS, Kelly SM, Lund JN et al. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005; 7(2): 182–186.

77. Shen B, Remzi FH, Lopez AR et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008; 8: 26. doi: 10.1186/1471-230X-8-26.

78. Papi C, Ciaco A, Koch M et al. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular ­Disease Study Group. Ital J Gastroenterol 1992; 24(8): 452–456.

79. Papi C, Ciaco A, Koch M et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controled trial. Aliment Pharmacol Ther 1995; 9(1): 33–39.

80. Latella G, Pimpo MT, Sottili S et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18(1): 55–62.

81. Pistoia MA, Lombardi L, Rossi M et al. Does rifaximin prevent complications of diverticular disease? A retrospective study. Eur Rev Med Pharmacol Sci 2004; 8(6): 283–287.

82. Colecchia A, Vestito A, Pasqui F et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007; 13(2): 264–269.

83. D´Inca R, Pomerri F, Vettorato MG et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther 2007; 25(7): 771–779.

84. Trivedi CD, Das KM. Emerging therapies for diverticular disease of the colon. J Clin Gastroenterol 2008; 42(10): 1145–1151. doi: 10.1097/MCG.0b013e318188adc1.

85. Bianchi M, Festa V, Moretti A et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther 2011; 33(8): 902–910. doi: 10.1111/j.1365-2036.2011.04606.x.

86. Calanni F, Renzulli C, Fogli MV et al. Comment on: Rifaximin in the treatment of irritable bowel syndrome. Is there a high risk for development of antimicrobial resistance? J Clin Gastroenterol 2013; 47: 814–815.

87. Stallinger S, Eller N, Högenauer C. Non-interventional study evaluating efficacy and tolerability of rifaximin for treat­ment of uncomplicated diverticular di­sease. Wien Klin Wochenschr 2014; 126(1–2): 9–14. doi: 10.1007/s00508-013-0447-7.